848084-18-4Relevant academic research and scientific papers
Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity
Hao, Yun-Peng,Liu, Zheng-Yu,Ning, Jin-Feng,Sun, Xun,Tang, Mei-Lin,Zhou, Lu
, (2020)
Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer death around the world. The current treatments of CRC exhibited high occurrence rate of side effects. Docetaxel (DTX), an important drug widely used in cancer c
Polyene taxane targeted prodrug and its anti-colon cancer pharmaceutical use
-
Paragraph 0025; 0027; 0028; 0029, (2019/03/26)
The invention belongs to the field of biological medicine, in particular to a novel polyene taxane targeted prodrug and its medicinal use, the present invention provides includes the general formula (1) represented by the new polyene taxane targeted prodr
MMP-SENSITIVE TAXANE PRODRUG
-
Page/Page column 12, (2017/07/08)
The present invention harnesses the differential expression of membrane-type matrix metalloproteinases (MT-MMPs) between human solid tumours and normal tissues to provide a systemically inactive prodrug which is selectively activated at the tumour micro-environment. The present invention provides a prodrug which is a conjugate of a taxane and a selective MT-MMP cleavable delivery vehicle.
COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE
-
Page/Page column 115, (2008/06/13)
Compounds for use in a diagnostic agent for detecting, imaging, and/or monitoring a pathological disorder associated with matrix metalloproteinase activity at a site of interest in a patient are disclosed. Compositions and kits containing the compounds are also disclosed. In addition, methods of detecting, imaging, and/or monitoring the presence of matrix metalloproteinase or a pathological disorder associated with matrix metalloproteinase activity in a patient are disclosed.
